Cellebrite DI (NASDAQ:CLBT) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of Cellebrite DI (NASDAQ:CLBT) from a buy rating to a hold rating in a research note published on Saturday morning.

Several other equities research analysts have also recently weighed in on the stock. Lake Street Capital dropped their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 15th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, August 14th. Weiss Ratings restated a “sell (d+)” rating on shares of Cellebrite DI in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their price objective on Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Cellebrite DI Trading Up 0.9%

NASDAQ CLBT opened at $15.40 on Friday. The firm has a market cap of $3.69 billion, a PE ratio of -20.26, a price-to-earnings-growth ratio of 3.16 and a beta of 1.28. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30. The stock has a 50-day moving average of $17.76 and a 200-day moving average of $16.77.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. During the same period last year, the company earned $0.10 EPS. Cellebrite DI’s revenue for the quarter was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities research analysts forecast that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. King Luther Capital Management Corp purchased a new position in Cellebrite DI during the 3rd quarter valued at about $5,582,000. Zions Bancorporation National Association UT bought a new position in shares of Cellebrite DI during the third quarter valued at approximately $1,161,000. Vanguard Group Inc. increased its stake in shares of Cellebrite DI by 12.8% during the third quarter. Vanguard Group Inc. now owns 103,658 shares of the company’s stock valued at $1,921,000 after purchasing an additional 11,739 shares in the last quarter. Fifth Third Bancorp purchased a new position in shares of Cellebrite DI during the third quarter valued at approximately $250,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of Cellebrite DI by 114.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,501 shares of the company’s stock worth $83,000 after purchasing an additional 2,403 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.